Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. Pathology / 病理學科所
  4. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
 
  • Details

Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations

Journal
Journal of Thoracic Oncology
Journal Volume
9
Journal Issue
8
Pages
1171-1179
Date Issued
2014
Author(s)
YEN-FU CHEN  
MIN-SHU HSIEH  
SHANG-GIN WU  
YIH-LEONG CHANG  
JIN-YUAN SHIH  
Liu Y.-N.
Tsai M.-F.
TZU-HSIU TSAI  
CHONG-JEN YU  
CHIH-HSIN YANG  
PAN-CHYR YANG  
DOI
10.1097/JTO.0000000000000232
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905815103&doi=10.1097%2fJTO.0000000000000232&partnerID=40&md5=94c4d7eac535bdcc656e5c003f6a2439
https://scholars.lib.ntu.edu.tw/handle/123456789/470804
Abstract
Introduction: The prevalence, demographic features, and clinical outcomes of lung adenocarcinoma patients with novel ROS1 oncogenic rearrangement in East Asian populations are not clear. This study aimed to investigate the clinical and prognostic characteristics of lung adenocarcinoma in patients with ROS1 fusion compared with other driver mutations. Methods: Multiplex reverse transcription-polymerase chain reaction was used to detect the ROS1 fusion gene in lung adenocarcinoma cases. Immunohistochemistry was used to confirm the expression of ROS1. The demographic data and clinical outcomes of patients with the ROS1 fusion gene were compared with those of patients without the ROS1 fusion gene, including those with the EGFR mutation, EML4-ALK fusion, KRAS mutation, and quadruple-negative patients. Results: Of 492 patients with lung adenocarcinoma, 12 (2.4%) had the ROS1 fusion gene. Their median age was 45.0 years, significantly younger than that of the ROS1 fusion-negative cohorts (p <0.001). Acinar (including cribriform) and solid patterns were the two most common histologic subtypes in the ROS1 fusion tumors (7 of 12, 58.3%) and were predominantly seen in CD74-ROS1 fusion tumors (66.7%). There was no significant survival difference between the ROS1 fusion-positive and ROS1 fusion-negative cohorts in surgical group, but ROS1 fusion-positive patients might have worse outcomes than EGFR-mutant patients in the stage IV group. Conclusions: The ROS1 fusion gene can be successfully detected in East Asian patients with lung adenocarcinoma using multiplex reverse transcription-polymerase chain reaction. These patients tend to be younger and have characteristic histologic subtypes. Due to the small number of ROS1 fusion patients, the prognostic value of ROS1 fusion need further studies to confirm. Copyright ? 2014 by the International Association for the Study of Lung.
SDGs

[SDGs]SDG3

Other Subjects
crizotinib; pemetrexed; B lymphocyte antigen; EGFR protein, human; EML4-ALK fusion protein, human; epidermal growth factor receptor; HLA antigen class 2; invariant chain; KRAS protein, human; oncoprotein; protein tyrosine kinase; Ras protein; ROS1 protein, human; SDC4 protein, human; SLC34A2 protein, human; sodium phosphate cotransporter 2b; syndecan 4; adult; aged; article; cancer patient; cancer prognosis; cd74 ros1 fusion gene; clinical feature; controlled study; female; fusion gene; gene expression; gene mutation; human; immunohistochemistry; lung adenocarcinoma; major clinical study; male; middle aged; multiplex polymerase chain reaction; population research; priority journal; prospective study; reverse transcription polymerase chain reaction; ROS1 gene; adenocarcinoma; age; Asian continental ancestry group; comparative study; disease free survival; genetics; Lung Neoplasms; mutation; pathology; prognosis; sex difference; survival rate; Taiwan; very elderly; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Asian Continental Ancestry Group; Disease-Free Survival; Female; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; ras Proteins; Receptor, Epidermal Growth Factor; Sex Factors; Sodium-Phosphate Cotransporter Proteins, Type IIb; Survival Rate; Syndecan-4; Taiwan
Publisher
Lippincott Williams and Wilkins
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science